-
Je něco špatně v tomto záznamu ?
Role of Adipose Tissue in Inflammatory Bowel Disease
E. Karaskova, M. Velganova-Veghova, M. Geryk, H. Foltenova, V. Kucerova, D. Karasek
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
FNOL 00098892
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
33921758
DOI
10.3390/ijms22084226
Knihovny.cz E-zdroje
- MeSH
- abdominální obezita imunologie metabolismus MeSH
- adipokiny metabolismus MeSH
- idiopatické střevní záněty imunologie metabolismus MeSH
- lidé MeSH
- nitrobřišní tuk imunologie metabolismus MeSH
- tuková tkáň imunologie metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Inflammatory bowel diseases (IBDs), chronic inflammatory disorders affecting the gastrointestinal tract, include Crohn's disease and ulcerative colitis. There are increasing clinical and experimental data showing that obesity, especially visceral adiposity, plays a substantial role in the pathogenesis of IBD. Obesity seems to be an important risk factor also for IBD disease severity and clinical outcomes. Visceral adipose tissue is an active multifunctional metabolic organ involved in lipid storage and immunological and endocrine activity. Bowel inflammation penetrates the surrounding adipose tissue along the mesentery. Mesenteric fat serves as a barrier to inflammation and controls immune responses to the translocation of gut bacteria. At the same time, mesenteric adipose tissue may be the principal source of cytokines and adipokines responsible for inflammatory processes associated with IBD. This review is particularly focusing on the potential role of adipokines in IBD pathogenesis and their possible use as promising therapeutic targets.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018814
- 003
- CZ-PrNML
- 005
- 20210830100359.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22084226 $2 doi
- 035 __
- $a (PubMed)33921758
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Karaskova, Eva $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 245 10
- $a Role of Adipose Tissue in Inflammatory Bowel Disease / $c E. Karaskova, M. Velganova-Veghova, M. Geryk, H. Foltenova, V. Kucerova, D. Karasek
- 520 9_
- $a Inflammatory bowel diseases (IBDs), chronic inflammatory disorders affecting the gastrointestinal tract, include Crohn's disease and ulcerative colitis. There are increasing clinical and experimental data showing that obesity, especially visceral adiposity, plays a substantial role in the pathogenesis of IBD. Obesity seems to be an important risk factor also for IBD disease severity and clinical outcomes. Visceral adipose tissue is an active multifunctional metabolic organ involved in lipid storage and immunological and endocrine activity. Bowel inflammation penetrates the surrounding adipose tissue along the mesentery. Mesenteric fat serves as a barrier to inflammation and controls immune responses to the translocation of gut bacteria. At the same time, mesenteric adipose tissue may be the principal source of cytokines and adipokines responsible for inflammatory processes associated with IBD. This review is particularly focusing on the potential role of adipokines in IBD pathogenesis and their possible use as promising therapeutic targets.
- 650 _2
- $a adipokiny $x metabolismus $7 D054392
- 650 _2
- $a tuková tkáň $x imunologie $x metabolismus $7 D000273
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatické střevní záněty $x imunologie $x metabolismus $7 D015212
- 650 _2
- $a nitrobřišní tuk $x imunologie $x metabolismus $7 D050152
- 650 _2
- $a abdominální obezita $x imunologie $x metabolismus $7 D056128
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Velganova-Veghova, Maria $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Geryk, Milos $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Foltenova, Hana $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Kucerova, Veronika $u Department of Clinical Biochemistry, University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 700 1_
- $a Karasek, David $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 8 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33921758 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100359 $b ABA008
- 999 __
- $a ok $b bmc $g 1689793 $s 1139260
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 8 $e 20210419 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a FNOL 00098892 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20210728